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Angiogenesis in renal 
failure
Cardiovascular morbidity and mortality 
are frequent companions of end-stage 
renal disease. Th e cause is obscure, but 
the cause-and-eff ect problem is serious: 
it could be that the original cause is 
cardiovascular disease, which results in 
renal disease. However, in experimental 
animals it is possible to defi ne the causal 
aspects more rigorously. As they report 
in this issue, Jacobi et al. produced severe 
renal failure by removing fi ve-sixths of 
the kidney mass in rats. Th e researchers 
then examined parameters of vascular 
function. Th ey produced ischemia in the 
hindlimbs and measured the resultant 
angiogenesis 2 weeks later. Using laser 
Doppler perfusion imaging, they found 
that hind-paw perfusion had returned 
to normal in control animals but was 
reduced in animals with severe renal 
failure. Using an immunocytochemical 
method that analyzes the density of 
capillary endothelia, they found that 
capillary densities were increased in 
sham-operated animals but were much 
lower in nephrectomized animals. 
Hindlimb perfusion was assessed by 
fl uorescent microspheres and found to 
be impaired in nephrectomized animals. 
Vascular endothelial growth factor 
(VEGF) as well as VEGF receptor 1 
and 2 mRNA was increased in ischemic 
hindlimbs of controls but not in animals 
with renal failure. Th ese remarkable 
results suggest that renal failure has 
drastic eff ects on the program of 
angiogenesis. Whether this contributes 
to peripheral vascular disease in chronic 
renal failure remains to be determined. 
See page 2013.
Treatment of IgA 
nephropathy: is there 
a controversy?
IgA nephropathy is the most common 
form of serious glomerulonephritis 
around the globe. Its clinical spectrum 
varies from mild hematuria with no 
renal impairment to a relentlessly 
progressive renal disease. Despite the 
prevalence of this disease, there is no 
agreed-on therapy, in part because 
the clinical picture is varied. Even 
for a given clinical picture, there 
seems to be some controversy over 
treatment, especially regarding the 
use of immunosuppressive agents. 
But many other therapies have been 
proposed — anticoagulation and 
antiplatelet therapies, fi sh oil, and so 
on. Controversy has long been known 
to be a boon to newspaper publishers; 
public interest increases if a topic is 
controversial and thus likely to sell 
newspapers. Such crass considerations 
aside, the editors of Kidney International 
thought the nephrology community 
should get the latest thoughts on 
treatments for IgA nephropathy 
from two groups of investigators 
who are oft en asked to present their 
diametrically opposed views. We 
asked two eminent investigators and 
their junior colleagues to present their 
arguments. Th ese two papers, included 
in this issue, represent an impressive 
and thoughtful analysis of a diffi  cult 
subject. Th ey also identify the need for 
future studies to help resolve some of 
the remaining issues in the treatment of 
IgA nephropathy. See page 1934.
Global prevalence 
of proteinuria in 
diabetes
Diabetes remains the major cause of 
end-stage renal disease in the world. 
Prevention is now a reality; but the 
fi rst step in prevention is to ‘know the 
enemy.’ As they report in this issue, 
Parving et al. studied the prevalence of 
proteinuria in diabetics with no known 
history of proteinuria or kidney disease. 
A total of 32 000 charts or patients were 
analyzed. Albumin/creatinine ratios 
were measured. Almost half of the study 
group had signifi cant proteinuria, and 
10% had albuminuria. For patients with 
the highest proteinuria, the independent 
risk factors were as expected: 
hypertension, retinopathy, ethnicity, 
duration of diabetes, and so on. Asian 
and Hispanic patients had the highest 
prevalence of a raised urinary albumin/
creatinine ratio, and Caucasians had 
the lowest likelihood of an increased 
albumin/creatinine ratio, possibly 
refl ecting their higher socioeconomic 
status. Th is astonishingly high rate of 
kidney dysfunction is a challenge to 
the global nephrology community. 
But the silver lining is, aft er all, that 
early detection and treatment can slow 
down or even reverse renal progression. 
However, the scale of the problem is 
massive, and the people most in need 
are those with the fewest resources. 
Hence, the makers of national health 
policy now ought to know the scale of 
the problem and what needs to be done. 
See page 2057.
